Oral doses of dexpramipexole lowered eosinophil counts by up to 80 percent and showed signs of improving lung function in a Phase II eosinophilic asthma trial.
List view / Grid view
severe eosinophilic asthma
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector
AstraZeneca today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option for Fasenra (benralizumab) and a new delivery method as a pre-filled, single-use auto-injector (the Fasenra pen) to the medicine’s product information in the European…